Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study.
Daphne Rivero-GallegosMayra MejíaHéctor I Rocha-GonzálezJuan C Huerta-CruzRamcés Falfán-ValenciaEspiridion Ramos-MartínezHeidegger N Mateos-ToledoMaría F Castillo-LópezYeimi K Rodríguez-TorresValeria Lira-BoussartJorge Rojas SerranoPublished in: Clinical rheumatology (2024)
Anti-PL7-positive ASSD patients had more extensive fibrosis and severe ILD than the anti-Jo1 subgroup. This information is clinically useful and has significant implications for managing these patients, suggesting the need for early consideration of concurrent immunosuppressive and antifibrotic therapy.
Keyphrases
- interstitial lung disease
- end stage renal disease
- systemic sclerosis
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- idiopathic pulmonary fibrosis
- squamous cell carcinoma
- healthcare
- clinical trial
- patient reported outcomes
- early onset
- bone marrow
- study protocol
- health information
- placebo controlled